Efficacy of Lipid Apheresis: Definitions and Influencing Factors
- 1 April 1995
- journal article
- research article
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 18 (4) , 210-215
- https://doi.org/10.1177/039139889501800406
Abstract
The comparison of efficiency of currently available lipid apheresis systems has been hampered by different definitions of efficacy and poorly controlled apheresis conditions. This paper suggests definitions of efficacy and standardization of its determinants. The acute efficacy of risk factor reduction reflects the relative decrease of pathogen by a single treatment session compared to preapheresis levels. Standardization of treated plasma volume in relation to the patients plasma volume and correction of changes in plasma volume during the procedure are mandatory. Its determination is most useful in the technical evaluation of new systems. The long-term efficacy of risk factor reduction as compared to baseline is determined by mean interapheresis levels of e.g. LDL-C in the pseudo-steady-state after about 3 months of regular treatment. It is the major criterion for potential regression of coronary artery disease and absolute average plasma levels of 120 ≤ mg/dl LDL-C should be attained. It is influenced by the acute efficacy of the system, apheresis frequency and rebound kinetics. The clinical efficacy is defined by apheresis induced reduction of coronary morbidity and mortality. It is influenced by long-term risk factor reduction, the selectivity of the system as well as the control of non-lipid risk factors. Apheresis related effects on coronary artery disease comprise functional improvements of hemorheology and vasomotion as well as morphological benefits like regression of luminal narrowing and plaque stabilization. In conclusion, the acute efficacy of apheresis systems should be determined under strictly controlled conditions; however, as apheresis independent factors influence long-term efficacy and, even more so, clinical efficacy of the treatment, differences between the available systems are blurred so that factors like costs and ease of handling may eventually significantly influence the choice of procedure.Keywords
This publication has 12 references indexed in Scilit:
- Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible MechanismsNew England Journal of Medicine, 1995
- The HELP‐LDL‐apheresis multicentre study, an angiographically assessed trial on the role of LDL‐apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL‐cholesterol plasma concentrations and the course of coronary heart disease*European Journal of Clinical Investigation, 1994
- Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical dataChemistry and Physics of Lipids, 1994
- Lipid Apheresis by Hemoperfusion: In Vitro Efficacy and Ex Vivo Biocompatibility of a New Low‐Density Lipoprotein Adsorber Compatible with Human Whole BloodArtificial Organs, 1993
- Progression and regression of coronary artery diseaseCurrent Opinion in Lipidology, 1992
- Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter studyAtherosclerosis, 1992
- The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease.European Journal of Clinical Investigation, 1991
- Treatment of familial hypocholesterolemia by means of specific immunoadsorptionJournal of Clinical Apheresis, 1988
- Regression der Koronarsklerose bei familiärer Hypercholesterinämie IIa durch spezifische LDL-AphereseDeutsche Medizinische Wochenschrift (1946), 1986
- Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985